CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 258 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01697462
NCT01697462N/ACompleted

Evaluation of Safety and Efficacy of Xeloda in Metastatic Colorectal Carcinoma

Hoffmann-La Roche·observational·Posted Oct 2, 2012·Updated Jan 26, 2016

In Brief

An observational study for Colorectal Cancer. Completed, enrolled 258 participants across 5 sites.

Detailed Summary

This prospective observational study will evaluate the safety and efficacy of Xeloda (capecitabine) administered in monotherapy in patients with metastatic colorectal cancer. Patients will be followed until disease progression or unacceptable toxicity occurs.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSerbia
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2, 2012
Enrollment StartJul 1, 2009
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 13.8 years ago